Tenax Therapeutics Inc (TENX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.94+8.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TENX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.2 | 1.2 | 0.4 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.2 | 1.2 | 0.4 |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | 0.0 | (0.1) | (0.1) | 0.0 | 0.0 |
| Operating Expenses & Income | |||||||||||||||
| Selling, General & Admin | — | — | — | — | — | 7.6 | 5.3 | 5.1 | 5.7 | 5.7 | 6.2 | 7.2 | 13.8 | 3.7 | 6.1 |
| R&D Expenses | 45.3 | 32.7 | 12.7 | 3.2 | 5.4 | 25.1 | 4.6 | 3.5 | 1.2 | 3.5 | 13.1 | 6.7 | 3.0 | 2.5 | 2.5 |
| Other Operating Expenses, Total | — | — | — | — | — | (0.3) | (0.0) | — | — | — | — | — | — | — | — |
| Operating Income | (68.6) | (56.4) | (19.5) | (8.2) | 11.1 | (32.7) | 9.9 | (8.6) | (6.9) | (9.2) | (52.7) | (14.8) | (16.6) | (5.2) | (8.2) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | 0.0 | 0.0 | 2.2 | 4.2 | 7.4 |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.1 | — | 0.0 | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (8.0) | 0.0 | — | — | — |
| Net Income | |||||||||||||||
| Net Income | (64.9) | (52.6) | (17.6) | (7.7) | 11.0 | (32.5) | (9.9) | (8.4) | (14.1) | (8.8) | (43.9) | (14.1) | (19.5) | (9.4) | (15.7) |
| Per Share | |||||||||||||||
| Basic EPS | (1.28) | (1.34) | (1.15) | (31.04) | — | — | — | — | — | — | — | (0.50) | (2.71) | (6.29) | (12.12) |
| Diluted EPS | (1.28) | (1.34) | (1.15) | (31.04) | — | — | — | — | — | — | — | (0.50) | (2.71) | (6.68) | (14.07) |
| Basic Weighted Avg Shares | 50.9 | 39.2 | 15.3 | 0.2 | — | — | — | — | — | — | — | 28.1 | 9.4 | 1.7 | 1.3 |
| Diluted Weighted Avg Shares | 50.9 | 39.2 | 15.3 | 0.2 | — | — | — | — | — | — | — | 28.1 | 9.4 | 1.8 | 1.4 |
| Supplemental | |||||||||||||||
| EBITDA | — | — | — | (8.2) | 11.1 | (32.7) | 9.9 | (8.6) | (6.9) | (9.2) | (52.6) | (14.7) | (16.5) | (5.0) | (8.0) |
| EBIT | (68.6) | (56.4) | (19.5) | (8.2) | 11.1 | (32.7) | 9.9 | (8.6) | (6.9) | (9.2) | (52.7) | (14.8) | (16.6) | (5.2) | (8.2) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.